RSV

RSV製品

All (5)
RSV阻害剤 (4)
RSV抗体(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S8588	ACSS2 inhibitor	ACSS2 inhibitor is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2). ACSS2 inhibitor also inhibits the respiratory syncytial virus (RSV).	Nat Commun, 2025, 16(1):2071 Cell Death Dis, 2025, 16(1):650 Cell Rep, 2025, 44(7):115947
S0470	RSV604	RSV604 (A-60444), a novel benzodiazepine, is an inhibitor of respiratory syncytial virus (RSV) with EC50 of 0.86 μM. RSV604 has significant potential for the effective treatment of RSV disease. Phase 2.	Biomed Environ Sci, 2023, 36(2):135-145
E1398	Rilematovir	Rilematovir (JNJ-678, JNJ-53718678) is an antiviral agent that inhibits respiratory syncytial virus (RSV) with EC50 of 1.2 nM in HBECs. Rilematovir is also a fusion protein inhibitor.
E1887^New	Sisunatovir hydrochloride	Sisunatovir hydrochloride (RV521 hydrochloride) is an orally available and potent inhibitor of the RSV-Fprotein with IC50 values of 1.4 nM and 1.0 nM for RSV A, RSV B, respectively. It effectively reduces RSV viral load and disease severity in humans and has demonstrated a good safety profile in the treatment of an established RSV infection.
A2364	Palivizumab (Anti-RSV-F)	Palivizumab (Anti-RSV-F) is a humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW : 145.5 kD.	N Biotechnol, 2025, 89:11-19
S8588	ACSS2 inhibitor	ACSS2 inhibitor is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2). ACSS2 inhibitor also inhibits the respiratory syncytial virus (RSV).	Nat Commun, 2025, 16(1):2071 Cell Death Dis, 2025, 16(1):650 Cell Rep, 2025, 44(7):115947
S0470	RSV604	RSV604 (A-60444), a novel benzodiazepine, is an inhibitor of respiratory syncytial virus (RSV) with EC50 of 0.86 μM. RSV604 has significant potential for the effective treatment of RSV disease. Phase 2.	Biomed Environ Sci, 2023, 36(2):135-145
E1398	Rilematovir	Rilematovir (JNJ-678, JNJ-53718678) is an antiviral agent that inhibits respiratory syncytial virus (RSV) with EC50 of 1.2 nM in HBECs. Rilematovir is also a fusion protein inhibitor.
E1887^New	Sisunatovir hydrochloride	Sisunatovir hydrochloride (RV521 hydrochloride) is an orally available and potent inhibitor of the RSV-Fprotein with IC50 values of 1.4 nM and 1.0 nM for RSV A, RSV B, respectively. It effectively reduces RSV viral load and disease severity in humans and has demonstrated a good safety profile in the treatment of an established RSV infection.
A2364	Palivizumab (Anti-RSV-F)	Palivizumab (Anti-RSV-F) is a humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW : 145.5 kD.	N Biotechnol, 2025, 89:11-19
E1887^New	Sisunatovir hydrochloride	Sisunatovir hydrochloride (RV521 hydrochloride) is an orally available and potent inhibitor of the RSV-Fprotein with IC50 values of 1.4 nM and 1.0 nM for RSV A, RSV B, respectively. It effectively reduces RSV viral load and disease severity in humans and has demonstrated a good safety profile in the treatment of an established RSV infection.